Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr. César López-Camacho

Vaccine development for infectious diseases and immunopathogenesis

PROFILE

César López-Camacho holds a PhD in Molecular Biology from the University of Manchester, United Kingdom, and has held four postdoctoral positions in molecular biology, fidelity of gene expression, and vaccinology at UMASS Medical School-USA, University of Vermont College of Medicine-USA and the Jenner Institute at University of Oxford, respectively. He is currently a Senior Postdoctoral Researcher working with Prof. Gavin Screaton at the Wellcome Centre for Human Genetics, here at Oxford. 

Since the COVID-19 outbreak, his current scientific activity encompasses the design and protein production of SARS-CoV-2 antigens to be utilised as diagnostic tools and for coronavirus research applications. He is part of both the COVID-19 Outbreak Expert Database for the UK parliament, and the National COVID Testing Scientific Advisory Panel.

In the pre-COVID era, his main research aims are the immunopathogenesis of Dengue virus and vaccine development of novel antigen candidates, to induce specific anti-flavivirus antibody responses against functional and conformational epitopes. 

Doctor López-Camacho joined the Jenner Institute in 2014 as a postdoctoral researcher in Reyes-Sandoval’s group and worked on vaccine development for several arboviruses (Zika, Dengue, Chikungunya and Mayaro viruses). During this time he published 14 papers, both as first author and as co-author, in relation to arboviral, parasitic (malaria and chagas disease) and Papillomavirus vaccine developments.

In terms of intellectual property activities, he is an inventor and collaborator in vaccine-related Patents.